||||||||||Anti-CD19 CAR-T / First Affiliated Hospital of Nanchang University, Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche Efficacy and Safety of CD19-Specific CAR-T Cell Therapy Following Immunochemotherapy in Newly Diagnosed B-Cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (SDCC - Halls G-H) - Nov 3, 2023 - Abstract #ASH2023ASH_6300; Importantly, no exacerbation of hemophagocytic syndrome occurred following CAR-T cell infusion, and no patients succumbed to adverse events. In conclusion, our findings suggest that CD19 CAR-T cell treatment exhibits high efficacy as part of first-line therapy for B-LAHS, with a manageable safety profile.
||||||||||Anti-CD19 CAR-T / First Affiliated Hospital of Nanchang University Retrospective data, Review, Journal: Efficacy and safety of dual-targeting chimeric antigen receptor-T therapy for relapsed or refractory B-cell lymphoid malignancies: a systematic review and meta-analysis. (Pubmed Central) - Mar 24, 2023 Dual-targeting chimeric antigen receptor (CAR)-T cell therapy has been proposed as a potential solution for overcoming antigen escape during anti-CD19 CAR-T treatment...This study demonstrates the safety and clinical efficacy of dual-targeting CAR-T cell therapies in B-cell malignancies. Further well-designed randomized controlled trials are required to establish the role of dual-targeting CAR-T cell therapy in patients with B-cell malignancies.